A biological composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa, and its preparation method and application

By using compositions of yeast mannan, sodium hyaluronate, isomaltose, chitosan and peppermint oil in the nasal cavity, the problem of difficulty in quickly reaching the nasal cavity by taking oral medication is solved, and the symptoms of rhinitis and nasal mucosa are quickly relieved. Repair, high security and stability.

CN117919302BActive Publication Date: 2024-11-05HUNAN TIANGENLE WEIJUN TECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311856083.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2024-11-05
Estimated Expiration
2043-12-29

AI Technical Summary

Technical Problem

Existing oral medications are difficult to reach the nasal cavity quickly and effectively, resulting in inefficient treatment of rhinitis and repairing nasal mucosa, and insufficient safety.

Method used

A composition is adopted, including 3 to 5 parts of yeast mannan, 0.5 to 2 parts of sodium hyaluronate, 0.1 to 0.5 parts of oligoisomaltose, 0.5 to 2 parts of chitosan and 0.05 to 1 part of peppermint oil, by Reasonably match sodium hyaluronate with different molecular weights to form anti-inflammatory, antioxidant and immunomodulatory compositions for direct application in the nasal cavity.

Benefits of technology

This composition can quickly relieve the symptoms of rhinitis and significantly repair the nasal mucosa. It has good product stability and clear components. It has no irritation to the nasal mucosa and local tissues, and is highly safe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004642245260000061
    Figure BDA0004642245260000061
  • Figure BDA0004642245260000071
    Figure BDA0004642245260000071
Patent Text Reader

Abstract

The present invention discloses a composition that can effectively relieve rhinitis symptoms and repair nasal mucosa, and a preparation method and application thereof, wherein the composition comprises: 3 to 5 parts of yeast mannan, 0.5 to 2 parts of sodium hyaluronate, 0.1 to 0.5 parts of oligomaltosan, 0.5 to 2 parts of chitosan and 0.05 to 1 parts of peppermint oil. The composition that can effectively relieve rhinitis symptoms and repair nasal mucosa of the present invention is to reasonably match sodium hyaluronate of different molecular weights with mannan, chitosan, oligomaltosan and peppermint oil, and to have a specific synergistic effect, while being able to effectively treat rhinitis, it can significantly repair the nasal mucosa, the product has good stability, clear components, no irritation to the nasal mucosa and local tissues, and high safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a biological composition capable of effectively alleviating rhinitis symptoms and repairing nasal mucosa, and a preparation method and application thereof. Background Art

[0002] Rhinitis is an acute or chronic inflammation of the nasal mucosa or submucosal tissue caused by damage to the nasal mucosa or submucosal tissue due to viral infection, bacterial infection, irritant stimulation, etc. Rhinitis causes excessive mucus production, usually causing symptoms such as runny nose and nasal congestion.

[0003] At present, there are many drugs for treating rhinitis, and the most commonly used ones are oral drugs. However, oral drugs need to be delivered to the nasal mucosa through the systemic circulation, so there are few drugs that can reach the nose, so they have the disadvantages of slow onset and low efficacy. It is urgent to develop new products with clear ingredients and safer treatment of rhinitis and repair of nasal mucosa. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention proposes a composition that can effectively relieve rhinitis symptoms and repair nasal mucosa, wherein the composition has clear ingredients and can effectively treat rhinitis and repair nasal mucosa.

[0005] The invention also provides a method for preparing the composition.

[0006] The invention also provides an application of the composition.

[0007] The invention also provides a medicine.

[0008] According to one aspect of the present invention, a composition that can effectively relieve rhinitis symptoms and repair nasal mucosa is provided, the composition comprising: 3 to 5 parts of yeast mannan, 0.5 to 2 parts of sodium hyaluronate, 0.1 to 0.5 parts of isomaltooligosaccharide, 0.5 to 2 parts of chitosan and 0.05 to 1 part of peppermint oil;

[0009] The sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate;

[0010] The molecular weight of the low molecular weight sodium hyaluronate is 20 kDa to 100 kDa;

[0011] The molecular weight of the medium molecular weight sodium hyaluronate is 200 kDa to 800 kDa;

[0012] The molecular weight of the high molecular weight sodium hyaluronate is 800 kDa to 1800 kDa.

[0013] In some embodiments of the present invention, the mass addition ratio of the low molecular weight sodium hyaluronate, the medium molecular weight sodium hyaluronate and the high molecular weight sodium hyaluronate is (2-4): (2-5): (3-5).

[0014] The present invention rationally matches and co-encapsulates three kinds of sodium hyaluronates of different molecular weights (low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate), and the comprehensive effect is outstanding, wherein, low molecular weight sodium hyaluronate can quickly penetrate into the cell interior, promote cell proliferation and repair, and also have good moisturizing effect, which helps to alleviate the symptoms such as nasal dryness and itching caused by rhinitis; medium molecular weight sodium hyaluronate has good adhesion, can form a protective film on the surface of nasal mucosa, reduce sensitivity to irritants, and prevent the occurrence of allergic reactions; high molecular weight sodium hyaluronate has large molecular weight and high viscosity, can cover the entire nasal cavity, form a more stable protective film, and help to continuously alleviate the symptoms of rhinitis. Mannan, chitosan, oligomaltose and peppermint oil are used in combination with different molecular weight sodium hyaluronates, have anti-inflammatory, antioxidant and immunomodulatory effects, can reduce the inflammatory reaction of nasal mucosa, relieve symptoms such as nasal congestion and runny nose, and improve the discomfort such as nasal congestion and itching caused by rhinitis, effectively treat rhinitis and repair nasal mucosa.

[0015] In some embodiments of the present invention, the composition further comprises 0.3 to 0.4 parts of a preservative and 0.03 to 0.06 parts of a pH adjuster.

[0016] In some embodiments of the present invention, the preservative includes at least one of sodium methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid or sodium sorbate.

[0017] In some embodiments of the invention, the pH adjuster comprises triethanolamine.

[0018] In some embodiments of the present invention, the composition further comprises water.

[0019] In the second aspect of the present invention, a method for preparing the above composition is proposed, comprising the following steps: mixing the components in the above composition.

[0020] In the third aspect of the present invention, an application of the above composition is proposed, wherein the application is application in preparing a product for treating rhinitis.

[0021] In some embodiments of the invention, the rhinitis comprises allergic rhinitis.

[0022] In some embodiments of the present invention, the application is application in preparing a product for repairing nasal mucosa.

[0023] In some embodiments of the present invention, the product is a drug or a medical device.

[0024] In some embodiments of the invention, the product is a drug.

[0025] In some embodiments of the present invention, the drug further comprises a pharmaceutical excipient.

[0026] In some embodiments of the present invention, the pharmaceutical excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

[0027] In some embodiments of the present invention, the product is in the form of one of powder, paste, gel, drops, suppositories, lozenges, granules, capsules, sprays, tablets, pills and solutions.

[0028] In a fourth aspect of the present invention, a product is provided, wherein the product comprises the above-mentioned composition, and the product is used for treating rhinitis or repairing nasal mucosa.

[0029] In some embodiments of the present invention, the articles include drugs and medical devices.

[0030] In some embodiments of the present invention, the drug further comprises a pharmaceutical excipient.

[0031] In some embodiments of the present invention, the pharmaceutical excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

[0032] In some embodiments of the present invention, the preparation is in the form of one of powder, paste, gel, drops, suppositories, lozenges, granules, capsules, sprays, tablets, pills and solutions.

[0033] According to some embodiments of the present invention, at least the following beneficial effects are achieved: the composition of the present invention that can effectively relieve the symptoms of rhinitis and repair the nasal mucosa is prepared by reasonably combining sodium hyaluronate of different molecular weights with mannan, chitosan, maltooligosaccharide and peppermint oil, so as to achieve a specific synergistic effect. While being able to effectively treat rhinitis, it can significantly repair the nasal mucosa. The product has good stability, clear components, is non-irritating to the nasal mucosa and local tissues, and has high safety. DETAILED DESCRIPTION

[0034] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0035] Unless otherwise specified, the experimental methods used in the examples are all conventional methods; the materials and reagents used, unless otherwise specified, are all reagents and materials available from commercial sources.

[0036] In the embodiments of the present invention, sodium hyaluronate with different molecular weights was purchased from Guangzhou Hongkong Trade Development Co., Ltd.

[0037] Example 1

[0038] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa comprises the following components in percentage by weight: 4% of yeast mannan, 0.3% of low molecular weight sodium hyaluronate with a molecular weight of 20 kDa-100 kDa, 0.4% of medium molecular weight sodium hyaluronate with a molecular weight of 200 kDa-800 kDa, 0.3% of high molecular weight sodium hyaluronate with a molecular weight of 800 kDa-1800 kDa, 0.3% of isomaltooligosaccharide, 0.8% of chitosan, 0.2% of peppermint oil, 0.4% of sodium methylparaben and 0.05% of triethanolamine, and the balance is water.

[0039] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa comprises the following steps:

[0040] The yeast mannan, low molecular weight sodium hyaluronate with a molecular weight of 20 kDa-100 kDa, medium molecular weight sodium hyaluronate with a molecular weight of 200 kDa-800 kDa, high molecular weight sodium hyaluronate with a molecular weight of 800 kDa-1800 kDa, isomalt oligosaccharide, chitosan, peppermint oil and sodium methylparaben are added to ultrapure water and mixed evenly, and then triethanolamine is added to adjust the pH value to 6.0 (5.0-7.0 is acceptable) for disinfection and packaging.

[0041] Example 2

[0042] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa comprises the following components in percentage by weight: 4% yeast mannan, 0.4% low molecular weight sodium hyaluronate with a molecular weight of 20 kDa-100 kDa, 0.2% medium molecular weight sodium hyaluronate with a molecular weight of 200 kDa-800 kDa, 0.4% high molecular weight sodium hyaluronate with a molecular weight of 800 kDa-1800 kDa, 0.3% isomalt oligosaccharide, 0.8% chitosan, 0.2% peppermint oil, 0.4% sodium methylparaben and 0.05% triethanolamine, and the balance is water.

[0043] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0044] Example 3

[0045] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa comprises the following components in percentage by weight: 4% of yeast mannan, 0.3% of low molecular weight sodium hyaluronate with a molecular weight of 20 kDa-100 kDa, 0.5% of medium molecular weight sodium hyaluronate with a molecular weight of 200 kDa-800 kDa, 0.2% of high molecular weight sodium hyaluronate with a molecular weight of 800 kDa-1800 kDa, 0.3% of isomaltooligosaccharide, 0.8% of chitosan, 0.2% of peppermint oil, 0.4% of sodium methylparaben and 0.05% of triethanolamine, and the balance is water.

[0046] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0047] Example 4

[0048] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa comprises the following components in percentage by weight: 3% of yeast mannan, 0.3% of low molecular weight sodium hyaluronate with a molecular weight of 20 kDa-100 kDa, 0.4% of medium molecular weight sodium hyaluronate with a molecular weight of 200 kDa-800 kDa, 0.3% of high molecular weight sodium hyaluronate with a molecular weight of 800 kDa-1800 kDa, 0.8% of isomaltooligosaccharide, 1.0% of chitosan, 0.4% of peppermint oil, 0.4% of sodium methylparaben and 0.05% of triethanolamine, and the balance is water.

[0049] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0050] Comparative Example 1

[0051] A composition that can effectively relieve rhinitis symptoms and repair nasal mucosa, which differs from Example 1 in that it does not contain low molecular weight sodium hyaluronate.

[0052] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0053] Comparative Example 2

[0054] A composition that can effectively relieve rhinitis symptoms and repair nasal mucosa, which differs from Example 1 in that it does not contain medium molecular weight sodium hyaluronate.

[0055] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0056] Comparative Example 3

[0057] A composition that can effectively relieve rhinitis symptoms and repair nasal mucosa, which differs from Example 1 in that it does not contain high molecular weight sodium hyaluronate.

[0058] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0059] Comparative Example 4

[0060] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa, which differs from Example 1 in that it does not contain yeast mannan.

[0061] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0062] Comparative Example 5

[0063] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa, which differs from Example 1 in that it does not contain isomaltooligosaccharide.

[0064] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0065] Comparative Example 6

[0066] A composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa, which differs from Example 1 in that it does not contain peppermint oil.

[0067] The preparation method of the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa is shown in Example 1.

[0068] Test Case

[0069] 1. Allergic rhinitis treatment experiment

[0070] Test methods

[0071] (1) Experimental animals

[0072] A total of 120 4-week-old SD rats (purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.) with a body weight (80±10g) were selected, half of which were male and half were female.

[0073] (2) Animal model of allergic rhinitis

[0074] SD rats were sensitized by intraperitoneal injection of 25 μg ovalbumin (OVA), 2 mg aluminum hydroxide, and 0.5 mL saline on days 0, 7, and 14. Then, SD rats were challenged with 100 μg OVA intranasally for 7 consecutive days from day 21 to day 27. The difference was that SD rats in the normal group were intraperitoneally injected with 0.5 mL saline and nasally dripped with saline (the same dose as the modeling group) until day 27.

[0075] (3) Experimental groups

[0076] 120 SD rats were randomly divided into 12 groups, namely: normal group, model group, Example 1 group, Example 2 group, Example 3 group, Example 4 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, Comparative Example 5 group, Comparative Example 6 group; 10 rats in each group.

[0077] On the 21st to 27th day (2 to 5 hours before OVA nasal challenge), drug treatment was started, and the composition prepared in the corresponding embodiment and comparative example, which can effectively relieve rhinitis symptoms and repair nasal mucosa, was administered once a day, 40 μg each time. The SD rats in the normal group were not treated with any measures; the SD rats with allergic rhinitis in the model group were administered with physiological saline once a day, and the dosage was the same as that in the embodiment group or the comparative example group.

[0078] (4) Evaluation indicators

[0079] Allergic rhinitis is a specific disease characterized by symptoms such as nasal congestion, nasal wiping, sneezing and nasal itching. Therefore, after the last OVA nasal challenge, the number of sneezes in SD rats within 30 minutes and 60 minutes, and the number of nose scratching within 15 minutes were recorded.

[0080] In addition, after the treatment, 0.7 mL of blood was collected from each SD rat, and the total IgE level and OVA-specific IgE level were measured using ELISA kits according to the manufacturer's instructions.

[0081] 1) Number of sneezes

[0082] Table 1

[0083] Group 30min 60min Example 1 3.2±0.8 5.6±0.4 Example 2 5.4±1.7 8.1±0.9 Example 3 3.7±1.2 7.1±1.2 Example 4 6.4±1.6 10.6±2.5 Comparative Example 1 12.5±2.6 19.4±3.2 Comparative Example 2 15.7±3.1 22.5±1.7 Comparative Example 3 11.6±2.7 21.7±4.2 Comparative Example 4 21.4±3.5 32.2±3.3 Comparative Example 5 14.3±2.4 18.4±2.6 Comparative Example 6 10.2±0.6 16.7±2.3 Model Group 65.7±6.4 78.6±5.1 Normal group 12.8±1.9 16.5±1.6

[0084] The results are shown in Table 1. It can be seen from the table that the number of sneezes of SD rats in the Example and Comparative Example groups after administration was significantly lower than that in the Model group.

[0085] 2) Nose scratching frequency

[0086] Table 2 Number of nose scratching of SD rats in each group

[0087]

[0088]

[0089] The results are shown in Table 2. After administration, the SD rats in the Example group and the Comparative Example group scratched their nose significantly less than those in the Model group; in particular, the nose scratching condition of the rats in the Example group was significantly improved, and the number of nose scratching of the rats was comparable to that of the rats in the Normal group.

[0090] 3) Total IgE levels and OVA-specific IgE levels in rat serum before and after treatment

[0091] Table 3 Total serum IgE levels and OVA-specific IgE levels of rats in each group after treatment

[0092] Group Total IgE level (ng / mL) OVA-specific IgE level (ng / mL) Example 1 478.2±57.6 0.9±0.3 Example 2 524.4±36.4 1.5±0.4 Example 3 516.7±39.7 1.2±0.1 Example 4 545.2±63.4 1.6±0.2 Comparative Example 1 1089.7±87.9 9.2±2.1 Comparative Example 2 1019.6±88.54 8.7±3.2 Comparative Example 3 977.1±64.3 8.4±2.5 Comparative Example 4 1207.4±106.3 13.7±2.8 Comparative Example 5 787.3±76.5 6.5±1.7 Comparative Example 6 723.5±69.4 5.1±0.9 Model Group 2247.2±124.3 20.7±1.5 Normal group 586.7±26.2 1.8±0.4

[0093] The results are shown in Table 3. After administration, the total IgE level and OVA-specific IgE level in the serum of SD rats in the embodiment group and the comparison group were significantly lower than those in the model group; and the total IgE level and OVA-specific IgE level in the serum of the rats in the embodiment group were significantly lower than those in the comparison group, which were equivalent to those in the normal group.

[0094] 4) Mucosal repair experiment

[0095] Nasal mucosal histological observation showed that there was almost no eosinophilic infiltration in the normal group. After repeated OVA antigen attack, the model group had nasal mucosal ulcers, nasal concha mucosal swelling, eosinophilic infiltration, glandular hyperplasia, and congestion and edema, especially EOS infiltration. After 7 days of continuous administration, the above pathological features of the treatment group were significantly improved, and EOS infiltration was significantly reduced.

[0096] Table 4

[0097] Group Nasal mucosal eosinophil count (cells) Example 1 2.3±0.5 Example 2 2.9±0.4 Example 3 2.6±0.2 Example 4 3.1±0.8 Comparative Example 1 5.9±1.1 Comparative Example 2 5.7±0.9 Comparative Example 3 5.4±1.3 Comparative Example 4 6.2±0.4 Comparative Example 5 4.1±1.3 Comparative Example 6 3.9±0.8 Model Group 8.3±0.9 Normal group 1.3±0.4

[0098] The results are shown in Table 4. It can be seen from the table that after administration of the Example and the Comparative Example groups, the EOS counts were reduced compared with the model group, indicating that administration of the composition of the present invention can effectively improve the inflammatory infiltration of the nasal mucosa of mice with allergic rhinitis.

[0099] 2. Clinical validation experiments

[0100] Forty patients with rhinitis accompanied by nasal mucosal damage aged 30-60 years were randomly selected, all of whom were informed consent patients, half of whom were male and half were female. The diagnostic content of all patients met the rhinitis diagnostic criteria currently issued by the Chinese Medical Association.

[0101] Randomly divide the patients into groups: each group has 20 patients, and the patients are respectively given the same amount of Example 1 and a commercially available rhinitis gel for trial experience, twice a day, and the test results are observed after 7 days.

[0102] Cure: The patient's clinical symptoms disappear, and nasal endoscopy shows no edema or secretions in the nasal mucosa;

[0103] Effective: The patient's clinical symptoms improved, and nasal mucosal edema and secretions improved after nasal endoscopy.

[0104] Ineffective: There was no change in the patient's clinical symptoms and signs.

[0105] Total clinical efficacy = (cured + effective) / total number of patients × 100%.

[0106] Table 5

[0107] Group Number of cases cure efficient Total Effectiveness Example 1 20 18 19 95% Commercially available rhinitis gel 20 14 18 90%

[0108] The results are shown in Table 5. It can be seen from the table that the composition capable of effectively relieving rhinitis symptoms and repairing nasal mucosa prepared in Example 1 of the present invention can effectively relieve rhinitis symptoms and has a certain repair effect on nasal mucosa.

[0109] The above content describes the embodiments of the present invention in detail, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A composition that can effectively relieve the symptoms of allergic rhinitis and repair nasal mucosa, characterized in that: The composition is composed of 3 to 5 parts of yeast mannan, 0.5 to 2 parts of sodium hyaluronate, 0.1 to 0.5 parts of isomaltooligosaccharide, 0.5 to 2 parts of chitosan and 0.05 to 1 part of peppermint oil; The sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate; The molecular weight of the low molecular weight sodium hyaluronate is 20 kDa to 100 kDa; The molecular weight of the medium molecular weight sodium hyaluronate is 200 kDa to 800 kDa; The molecular weight of the high molecular weight sodium hyaluronate is 800 kDa~1800 kDa; the mass addition ratio of the low molecular weight sodium hyaluronate, the medium molecular weight sodium hyaluronate and the high molecular weight sodium hyaluronate is (2~4):(2~5):(3~5).

2. A composition that can effectively relieve the symptoms of allergic rhinitis and repair nasal mucosa, characterized in that: The composition is composed of 3 to 5 parts of yeast mannan, 0.5 to 2 parts of sodium hyaluronate, 0.1 to 0.5 parts of isomaltooligosaccharide, 0.5 to 2 parts of chitosan, 0.05 to 1 parts of peppermint oil, 0.3 to 0.4 parts of preservatives and 0.03 to 0.06 parts of pH regulator; The sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate; The molecular weight of the low molecular weight sodium hyaluronate is 20 kDa to 100 kDa; The molecular weight of the medium molecular weight sodium hyaluronate is 200 kDa to 800 kDa; The molecular weight of the high molecular weight sodium hyaluronate is 800 kDa~1800 kDa; the mass addition ratio of the low molecular weight sodium hyaluronate, the medium molecular weight sodium hyaluronate and the high molecular weight sodium hyaluronate is (2~4):(2~5):(3~5).

3. The composition according to claim 2, characterized in that The preservative includes at least one of sodium methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid or sodium sorbate.

4. The composition according to claim 2, characterized in that The pH adjuster includes triethanolamine.

5. A method for preparing the composition according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: mixing the components.

6. Use of the composition according to any one of claims 1 to 4 in the preparation of a product for treating allergic rhinitis.

7. Use of the composition according to any one of claims 1 to 4 in preparing a product for repairing nasal mucosa.

8. A product that can effectively relieve the symptoms of allergic rhinitis and repair nasal mucosa, characterized in that: The article comprises the composition according to any one of claims 1 to 4.

9. The product according to claim 8, characterized in that The product is a medicine or a medical device.

10. The product according to claim 9, characterized in that The medicine also includes pharmaceutical excipients.

11. The product according to claim 10, characterized in that More preferably, the pharmaceutical excipients include at least one of a diluent, an excipient, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

12. The article according to claim 8, characterized in that The preparation is in the form of one of powder, paste, gel, drops, suppositories, lozenges, granules, capsules, sprays, tablets, pills and solutions.

Citation Information

Patent Citations

  • Nasal cavity in-situ gel spray containing menthol and preparation method of same

    CN106727277A

  • Preparation method of composite hydrogel for nasal cavity

    CN111135141A

  • Anti-allergic rhinitis composition as well as preparation method and application thereof

    CN115998761A

  • Allergic diathesis improver containing mannan of saccharomyces yeast as effective component

    JP2004224772A